Woburn biotech to lay off more than 200 after second FDA rejection of skin cancer treatment
Massachusetts biotech Replimune laid off more than 200 employees Friday after the Food and Drug Administration doubled down on its rejection of the company’s treatment for advanced skin cancer. The layoffs among its US workers include employees across all …